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Older women experience a large share of breast cancer incidence and death. With 
the projected rise in the number of older cancer patients, adjuvant chemo-, radiation 
and endocrine therapy management will become a key component of breast cancer 
treatment in older women. Many factors influence adjuvant treatment decisions 
including patient preferences, life expectancy and tumor biology. Geriatric assessment 
predicts important outcomes, identifies key deficits, and can aid in the decision 
making process. This review utilizes clinical vignettes to illustrate core principles in 
adjuvant management of breast cancer in older women and suggests an approach 
incorporating life expectancy and geriatric assessment.
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Two 70-year-old women present to discuss adjuvant 
treatment for breast cancer.
Mrs A has a history of osteoarthritis. She self-
detected a right breast lump during personal care. She 
lives with her ailing sister and assists with her care. She 
reports walking 2 miles per day and has no difficulty 
pulling heavy objects. Her BMI is 28. She has not 
been hospitalized in the past year and rates her general 
health as very good.
Mrs B has a history of Alzheimer’s dementia. She 
lives with her daughter who manages her medications 
and finances. Her daughter noticed a right breast lump 
while assisting her mother with personal care. Mrs B 
ambulates with a walker but is unable to walk more 
than ¼ mile and has difficulty pulling heavy objects. 
Her BMI is 19. She has been admitted to the hospital 
twice in the past year, most recently for a fall and rates 
her general health as fair.
Both women are lifelong nonsmokers and except 
for the palpable breast lumps have unremarkable 
physical examination findings. Imaging confirms 
the right breast masses. Core needle biopsy reveals 
grade 2, invasive ductal carcinoma. Immunohisto-
chemical stains show 99% of tumor cells express-
ing estrogen (ER) and progesterone (PR) receptors 
but <10% (score 0) stains for the human epidermal 
growth factor receptor 2 (HER-2/neu). A fluorescent 
in situ hybridization probe confirms that HER-2/neu 
is not overexpressed. Both women undergo lumpec-
tomy and sentinel lymph node evaluation. Pathologic 
specimens reveal a 3.1 cm, grade 2 invasive ductal can-
cer with no sentinel lymph nodes involved by cancer, 
that is, stage IIA (pT2, N0).
Background
It is estimated that in 2015 breast cancer will be the most 
frequently diagnosed malignancy among women in the 
USA, representing approximately 14% (231,840 people) 
of all new cancer cases and will be the third leading 
cause of mortality among women, accounting for an 
estimated 40,290 deaths [1]. The incidence of breast 
cancer rises dramatically with age, which is the single 
most important risk factor for developing cancer. As a 
result, a large proportion (41%) of all new breast can-
cer diagnoses and the majority of breast cancer deaths 
(58%) occur in women 65 years and older [1]. In fact, the 
median age at breast cancer diagnosis and death in the 
USA is 61 and 68 years, respectively [1]. These statistics 
are expected to change dramatically in the years ahead 
as a result of increasing life expectancy and an overall 
aging of the US population [2]. By 2030, the proportion 
of older adults (65 years and older) is projected to almost 
double from 14 to 20% of the total US population – one 
in every five persons or 70 million people [3]. Providing 
high level care for an increasing number of older breast 
cancer patients is of critical importance and will require 
health care providers and support staff who are trained 
in evaluating and treating this patient population.
Most breast cancers in older women are identified at 
an early, treatable stage [4] and the majority of women 
diagnosed with early stage breast cancer enjoy pro-
longed disease free survival [5]. Yet, recurrent disease 
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remains a persistent and vexing problem [6]. Those with 
loco-regional recurrences will require additional sur-
gery and other therapies while those who develop dis-
tant metastases are considered incurable with current 
therapies and most will eventually succumb to their ill-
ness. Thus, adjuvant therapies defined as treatments – 
chemotherapy, radiation or endocrine therapy – usually 
offered after primary surgery in an effort to decrease 
the risk of breast cancer recurrence and improve the 
odds of long-term disease-free survival have become 
key a component of breast cancer management.
Older breast cancer patients have not enjoyed as 
much improvement in survival from recent advances 
in adjuvant treatment as their younger counterparts [7]. 
In part, this disparity reflects uncertainties about the 
value of treatments, such as adjuvant chemotherapy, for 
older women, and its frequent lack of use even when 
appropriate. Deciding which patients are optimal can-
didates for adjuvant treatment in light of the potent 
toxicities as well as potential benefits of adjuvant treat-
ment is challenging [8]. Older women with unfavorable 
breast cancer subtypes are reasonable candidates for 
chemotherapy but many will be ineligible because of 
significant comorbidities. The aging process is charac-
terized by a variable decline in organ function [9,10] and 
the accumulation of comorbid medical conditions [11] 
that can vary greatly between older people of the same 
age. This inherent heterogeneity can result in two simi-
larly aged individuals – like the ones in the vignettes 
above, having vastly different general health, physical, 
cognitive and functional status. In addition, older can-
cer patients may have different and varied values, goals 
and preferences with respect to the trade-off between 
longevity and quality of life [12]. The purpose of this 
review is to illustrate key concepts and principles in the 
decision process and management of adjuvant therapies 
for older women with early stage breast cancer. Our 
aim is to discuss adjuvant treatment options for older 
women with breast cancer focusing on three areas: 
patient goals, beliefs, preferences and quality of life 
considerations; evaluation of the older patient’s fitness 
and suitability as defined by life expectancy, geriatric 
assessment, biologic, nodal and tumor differences; and 
to define the role of adjuvant treatment options, includ-
ing chemotherapy, endocrine and radiation therapy 
and tools to assist in decision making.
Primary endocrine therapy
Although the main focus of this paper is adjuvant 
therapies (i.e., after surgery), declining performance 
status and organ function as well as increasing comor-
bidity renders many older women with localized breast 
cancer suboptimal candidates for surgery. In these 
patients a discussion of primary endocrine therapy is 
warranted. Treatment with endocrine therapy as an ini-
tial approach, without removal of the primary tumor 
(i.e., primary endocrine therapy), has been evaluated in 
women who are not surgical candidates or decline oper-
ative intervention and is a reasonable option for such 
patients [13]. The role of primary endocrine therapy for 
women who are surgical candidates remains controver-
sial with most studies showing inferior local control but 
no convincingly different overall survival [14].
A 2007 Cochrane review analyzed data from clinical 
trials enrolling women 70 years and older with operable 
breast cancer who were fit for surgery comparing mas-
tectomy or wide local excision with or without tamoxi-
fen to tamoxifen alone [15]. This systematic review 
found no difference in survival when surgery either with 
(n = 1076; hazard ratio [HR]: 0.86; 95% CI: 0.73–1.00; 
p = 0.06) or without (n = 495; HR: 0.98; 95% CI: 
0.74–1.30; p = 0.9) adjuvant tamoxifen was com-
pared with tamoxifen alone. However, compared with 
tamoxifen alone there was a significant difference in 
progression free survival favoring surgery either with 
(HR: 0.65 [n = 1076; 95% CI: 0.53–0.81; p = 0.0001]) 
or without (HR: 0.55; 95% CI: 0.39–0.77; p = 0.0006) 
tamoxifen therapy. It is worth noting that this review 
included clinical trials of women with unselected hor-
mone receptor status. Tamoxifen is not effective or 
indicated in HR receptor negative breast cancer and 
this may have resulted in the underperformance of the 
primary endocrine therapy arm.
A 2014 meta-analysis documented similar findings 
with data from nonrandomized studies suggesting a 
survival advantage favoring surgery possibly resulting 
from selection of frail or unfit patients for treatment in 
the primary endocrine therapy group [16]. Recent long 
term updates of the Phase III (GRETA) trial showed 
inferior local control rates with tamoxifen alone ver-
sus surgery plus adjuvant tamoxifen but reported more 
favorable distant metastases free survival in women 
who took tamoxifen alone (48.8 vs 37.9 months; 
p = 0.009) [17]. The study found no difference between 
groups in the rate of distant metastases, disease-free 
survival, breast cancer and overall survival. Taken 
together these results suggest that primary endocrine 
therapy is a reasonable option for fit older women with 
early breast cancer who wish to delay or decline ini-
tial surgery. More recently trials of aromatase inhibi-
tors as primary endocrine therapy have found them to 
be effective in this setting and may be a better initial 
option for many older patients.
Treatment goals, patient beliefs  
& preferences
Many factors influence the decision to pursue or forego 
adjuvant therapy in older cancer patients. In this 
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review, we present the complex trade-off between ben-
efits and risks of adjuvant therapies to be conveyed to 
and weighed by the individual patient in light of their 
own particular treatment goals, beliefs about treatment 
risks and benefits, and preferences regarding near- and 
long-term outcomes. Although older patients have been 
shown to be as agreeable to undergo chemotherapy as 
younger patients, older patients often differ in their 
willingness to trade increased survival potential for 
decreased quality of life in survivorship [12,18]. Older 
patients generally value life without excessive fatigue, 
heightened anxiety and/or depression over an extended 
lifespan complicated by these issues [19]. While most 
older patients are willing to undergo a high treatment 
burden for improvements in survival, the vast majority 
would decline therapies that resulted in severe func-
tional (74%) or cognitive (89%) impairments [20]. 
Thus, regardless of the estimated benefits and risks of 
a particular treatment, older patients may have differ-
ent personal preferences when making treatment deci-
sions. Eliciting and respecting patient goals, beliefs 
and preferences with regard to adjuvant treatment is a 
critical step in the decision-making process.
Evaluation of older women with breast 
cancer
In this section, we describe three major consider-
ations in the determination of treatment options for 
older breast cancer patients: findings from a geriatric 
assessment, calculation of average life expectancy and 
specific biologic, tumor and nodal characteristics.
Geriatric assessment
In addition to a standard medical history and physical 
examination and assessment of tumor characteristics 
and organ function, oncology providers have tradition-
ally considered chronological age and basic measures 
of functional status such as the Karnofsky (KPS) [21] or 
the Eastern Cooperative Oncology Group [22] perfor-
mance status as the major factors for making adjuvant 
chemotherapy decisions. For older patients, however, 
the heterogeneous process of aging can limit the utility 
of chronologic age and performance status measures 
that have not been specifically validated in older adults 
and are not sufficiently sensitive to identify important 
deficits in function, cognition, psychosocial and other 
geriatric domains [23]. Figure 1 introduces the concept 
of the geriatric oncology iceberg illustrating that many 
factors which may influence adjuvant treatment deci-
sions and impact outcomes in older women with breast 
cancer are not always evident when considering age, 
traditional performance status measures, organ func-
tion and tumor characteristics. Multidimensional, 
interdisciplinary geriatric assessment (GA) offers a 
more thorough approach to evaluating the fitness of 
older cancer patients for various adjuvant therapies. In 
fact, the International Society of Geriatric Oncology 
recently recommended use of GA for all older adults 
with cancer to identify patient deficits, and better 
understand a patient’s functional age. Geriatric assess-
ment allows for characterization of a patient’s function 
into three groups; fit, vulnerable and frail to assist with 
clinical decision making [24].
Most GAs include domains of functional status, 
comorbidity, medication use, nutritional status, social 
status, cognition and psychological concerns using a 
variety of reliable and valid measurements. Specifi-
cally in older women with breast cancer, the GA has 
been used to determine frailty, estimate survival [25,26] 
and predict chemotherapy toxicity [27–30]. The GA 
can also detect issues that may affect cancer treatment 
tolerability such as cognitive impairment, depression, 
nutritional deficits and identification of falls [31,32]. In 
a recent study of 796 older cancer patients with ‘nor-
mal’ interviewer- and self-assessed KPS, GA identi-
fied at least one functional, psychosocial or nutritional 
deficit, comorbid illness or polypharmacy in more than 
two-thirds (68%) of study participants [33]. Timely 
identification of such deficits and subsequent interven-
tion with supportive services could decrease disability, 
institutionalization and cost as well as improve the 
quality of life in older women with cancer [31,32]. For 
example, services such as physical and occupational 
therapy (OT/PT) can be used to address poor endur-
ance, fatigue, strength or decline in activities of daily 
living and instrumental activities of daily living [34,35]. 
Early recognition of these functional deficits and 
timely referrals can decrease long-term disability [36]. 
Other services, such as nutrition, psychiatry, geriatrics 
and pharmacy consultation can also be used to rem-
edy potentially modifiable deficits that are often not 
identified and therefore potentially unaddressed in 
routine oncology practice. A full GA is time intensive 
and requires specialized personnel and resources; how-
ever, abbreviated GAs have been shown to be feasible 
in a variety of settings including a co-operative group 
clinical trial, academic medical center and community 
oncology practices [37–39].
Life expectancy
In addition to patient perspectives on their treatment 
options and findings from a brief GA, a further con-
sideration in estimating potential benefits of adju-
vant therapy is the patient’s estimated life expectancy 
– independent of their breast cancer, to determine 
whether they are likely to live long enough to benefit 
from the treatment. Chronologic age is an integral 
component of such estimates; however, it is by no 
CME
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means a sufficient consideration. As our two clinical 
cases illustrate, two 70-year-old breast cancer patients 
can have very different underlying health, physical 
activity and social support systems and require a treat-
ment approach that reflects these differences (Figure 1). 
It can be particularly challenging for physicians to esti-
mate the life expectancy of their patients, especially for 
patients in advanced stages of cancer [40]. Fortunately, 
several tools are available to aid in the estimation of 
life expectancy in a variety of different patient popula-
tions (e.g., community dwelling or nursing home) and 
life expectancy time frame [41]. Many of these tools are 
available in an online calculator format on the ‘eProg-
nosis’ website [42]. For example, the Lee–Schonberg 
index takes into account the patient’s age, gender, BMI, 
comorbidities, cigarette smoking, physical activity, 
previous hospitalizations and limitations in activities 
of daily living due to physical, mental, emotional or 
cognitive problems to estimate the patient’s life expec-
tancy [43–46]. None of these tools are perfect, but they 
provide reasonable estimates and are generally better 
than a subjective guess. Obtaining an accurate assess-
ment of a patient’s life expectancy irrespective of their 
current cancer provides a broader context in which to 
frame potential cancer treatment options.
Biologic, tumor & nodal characteristics
Invasive breast cancer can be divided into three bio-
logic subtypes: estrogen and/or progesterone recep-
tor positive (also called hormone receptor/HR posi-
tive) and human epidermal growth factor receptor-2 
(HER-2) negative; HER-2 positive, and estrogen and 
progesterone receptor negative and HER-2 negative 
(so-called ‘triple negative’ breast cancer; see Table 1). 
This subdivision of breast cancer into biologic sub-
types is helpful in providing prognostic information to 
CME
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patients and also aids the clinician in selecting thera-
peutic options. In addition, biologic subtypes correlate 
with breast cancer molecular subtypes as defined by 
molecular based genetic methods, including luminal 
A, luminal B and basal-like [47]. The early stage tumors 
commonly identified in older breast cancer patients 
tend to have more favorable biologic characteristics and 
are associated with a more favorable prognosis [47,48].
Patients with hormone receptor positive, HER-2 neg-
ative breast cancer represent approximately 70% of older 
patients with early stage breast cancer [48]. Most of these 
patients have luminal A and luminal B breast cancers, 
with luminal A cancers having an excellent long-term 
prognosis especially if they are diagnosed when they are 
small (≤2 cm in largest diameter) and have no involve-
ment of axillary lymph nodes [5]. The majority of these 
patients are generally considered for adjuvant endocrine 
therapy with agents that either block the effect of circu-
lating estrogens (tamoxifen) or lower circulating estro-
gens (aromatase inhibitors – such as anastrozole, letro-
zole and exemestane). When added to optimal surgery 
and radiation therapy (if appropriate), these endocrine 
agents lower risk of recurrence in both the breast and 
chest wall as well as in distant metastatic sites (bone, 
lung, liver or other organs) by about half [49,50].
Some patients at the time of surgery are found to have 
involvement of adjacent lymph nodes (node-positive). 
The hazard ratio for relapse (breast cancer recurrence) 
is much higher in women with node positive disease 
and typically occurs during the first 5 years after diag-
nosis. There also remains a small risk of yearly recur-
rence which persists for as long as 15–20 years after 
diagnosis and possibly even longer [51]. This may have 
implications in therapy selection for older patients with 
shorter life expectancies.
HER-2 positive breast cancers are seen in approxi-
mately 15% of older patients. These cancers are biologi-
cally more aggressive and tend to recur within the first 5 
years of the initial diagnosis and treatment. Patients with 
hormone receptor positive, HER-2 positive breast cancer 
have somewhat better long-term prognosis than those 
with hormone receptor negativity. Patients with hor-
mone receptor negative HER-2 positive breast cancers, 
if untreated with chemotherapy and HER-2 directed 
therapy, have the poorest survival. These patients, unless 
they have extremely short life expectancy, should be con-
sidered for cancer treatment, since the majority of recur-
rences in these patients are in the first several years after 
diagnosis. Options for chemotherapy and anti-HER-2 
directed therapy are discussed below (Table 2).
Approximately 15% of older patients have triple 
negative breast cancers. These represent the most 
aggressive breast cancers with the majority of recur-
rences occurring within the first several years after 
treatment. Endocrine therapy has no role in manage-
ment of triple negative breast cancer and thus adju-
vant chemotherapy is a major consideration. However, 
emerging data suggest that triple negative breast cancer 
expressing the androgen receptor (AR) may respond 
to AR inhibition [58]. More aggressive chemotherapy 
regimens may afford better long-term outcomes but at 
the risk of greater toxicity. The risk of recurrence and 
response to therapy for triple negative breast cancers is 
not affected by age.
Adjuvant chemotherapy
Estimating the benefit of chemotherapy
Not all women with breast cancer derive benefit from 
adjuvant chemotherapy. In fact, many older women (age 
>70) with hormone receptor positive early stage breast 
cancer treated with adjuvant chemotherapy will not 
accrue a survival advantage despite a reduction in the risk 
of relapse [8]. At issue is the clinical challenge of identify-
ing patients who are most likely to benefit from adjuvant 
Table 1. Biologic characteristics and management of breast cancer.
Type/frequency Molecular subtypes Treatment Comment
Hormone receptor positive  
(ER and/or PR) and HER-2 
negative (about 70% of breast 
cancer in older women)
Luminal A Endocrine therapy 
for most patients, 
chemotherapy for some 
patients
New genetic based assays can 
help select which patients should 
consider chemotherapy. Most 
patients relapse >5 years
HER-2 positive any ER or PR 
(about 15%)
Luminal B and HER-2 
expressing
Chemotherapy and 
anti-HER-2 therapy for 
most patients Endocrine 
Rx if hormone receptor 
positive
Major improvements in outcome 
with anti-HER-2 Rx. Most relapse 
patients <5 years
ER and PR and HER-2 negative 
‘triple negative’ (about 15%)
Basal-like Chemotherapy for most 
patients
More common in younger patients 
and African–American patients 
more chemotherapy is better. Most 
patients relapse <5 years
CME
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chemotherapy. This is particularly important in older 
women where noncancer related causes of mortality 
can eclipse cancer related causes [59]. To this end, multi-
variable prognostic indices have been developed which 
utilize clinical and tumor characteristics to estimate the 
benefit of adjuvant endocrine and chemotherapy treat-
ment. For example, Adjuvant! Online [60] incorporates 
age and comorbidities to estimate their impact on treat-
ment benefit and survival, and Predict [61] estimates the 
added survival benefit of adjuvant trastuzumab therapy 
in addition to chemotherapy and endocrine therapy. 
Both tools have been validated in large cohort studies of 
women with breast cancer and provide general estimates 
of the benefits of various adjuvant therapies; however, 
they are limited in their application to any individual 
patient’s circumstances.
To overcome this shortcoming, multigene prognos-
tic assays – such as the 21-gene Oncotype DX® – have 
been developed and validated in hormone receptor 
positive, node negative breast cancer patients to pre-
dict the risk of recurrence and estimate added value t of 
adjuvant chemotherapy in addition to endocrine ther-
apy [62]. These assays may influence treatment decisions 
in older women with early breast cancer who have a 
high risk of recurrence based on proprietary recurrence 
scores. If there is a discrepancy between the estimated 
risks of recurrence based on gene-based assays and clin-
ical characteristics a balanced discussion of the optimal 
approach should ensue. In clinical practice in the USA 
and Europe, chemotherapy is considered if there is an 
estimated 3–5% 10 year survival benefit [63].
Risk of chemotherapy toxicity
Chemotherapy toxicity is a key consideration in adju-
vant treatment decisions. Although overall chemother-
apy-related mortality is low (∼1% in general), older 
Table 2. Common adjuvant therapy regimens doses and schedules.
Medication/regimen Dose Schedule  Ref.
Endocrine therapies 




























































AC every 2 weeks for 4 cycles and 
paclitaxel every 2 weeks for 4 cycles 











4 mg/kg loading dose 
then 2 mg/kg/week
Every 3 weeks for 6 cycles followed 
by single agent trastuzumab to 






4 mg/kg loading dose 
then 2 mg/kg/week
Every week for 12 cycles followed 
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cancer patients are more susceptible to chemotherapy 
toxicities as compared with their younger counter-
parts [64,65]. Further, chemotherapy may exacerbate an 
older cancer patient’s other medical comorbidities, and 
even low grade toxicities such as diarrhea and neuropa-
thy may be sufficient to cause functional incontinence 
and decline in patients with pre-existing diabetic neu-
ropathy or limited mobility. In a pivotal study, Hur-
ria et al. investigated factors associated with chemother-
apy toxicity. In addition to demographic and standard 
clinical variables such as age, cancer type, chemother-
apy dose and creatinine clearance, their study found 
that deficits identified by GA such as hearing impair-
ment, limited physical function, falls and hearing 
impairment predicted risk of grade 3–5 chemotherapy 
toxicity in older patients whereas the Karnofsky Perfor-
mance Status measure did not [30]. Similarly, tools such 
as the Chemotherapy Risk Assessment Scale for High-
Age Patient (CRASH) score can provide estimates of a 
patient’s risk of chemotherapy toxicity and help tailor 
therapy as needed [66].
Selecting adjuvant chemotherapy for older 
women
Limited data exist to guide optimal adjuvant chemo-
therapy treatment decisions in women age 70 and older 
with early stage breast cancer. Nevertheless, prospec-
tive trial data suggest that the benefit older women 
derive from adjuvant chemotherapy is similar to that 
conferred on their younger counterparts [67]. Table 2 
provides an overview of common adjuvant chemother-
apy regimens used in the treatment of women with 
breast cancer. Adjuvant chemotherapy is relatively well 
tolerated in medically fit older women and the same 
general principles apply in selecting adjuvant chemo-
therapy as in younger women. However, the general 
decline in physiologic reserve and increase in comor-
bidities predispose older women to increased risk of 
toxicity which, in turn, may impact overall function, 
quality of life and survival [65,68]. Of particular concern 
is the risk of cardiac toxicity and secondary hemato-
logic malignancies with anthracycline-based chemo-
therapy regimens [69–71]. Selection of therapy for older 
women should therefore be individualized taking into 
consideration comorbid illnesses and other factors as 
recommended by the National Comprehensive Cancer 
Network [72].
Adjuvant radiation
The role for adjuvant radiation in older women with 
breast cancer follows the general principles of treat-
ment in the breast conserving and postmastectomy 
settings. Adjuvant radiation is indicated for node posi-
tive breast cancer, which confers a survival advantage. 
The value of nodal radiation for patients who have 
achieved a pathologic complete response to neoadju-
vant chemotherapy is a topic of ongoing clinical trials. 
There is a clear-cut local control benefit in the breast 
conservation setting, but the incremental benefit var-
ies widely depending on tumor size, tumor grade, 
hormone receptor and HER-2/neu status. For some 
women with favorable prognostic features (e.g., <2cm 
node negative and hormone receptor positive tumors), 
who are appropriate candidates for adjuvant endocrine 
therapy, adjuvant radiation may be safely omitted. For 
example, in a seminal study Hughes et al. [73,74] ran-
domized women 70 years and older with breast can-
cer to lumpectomy and tamoxifen with or without 
radiation. They found no difference in time to distant 
metastases, time to mastectomy, breast cancer specific 
survival, 5-year or 10-year overall survival despite a 
slightly higher (∼3% at 5 years and 8% at 10 years) rate 
of locoregional recurrence in the nonirradiated group. 
Table 3 summarizes the relevant randomized trials and 
meta-analyses evaluating omission of radiation in older 
breast cancer patients.
When the risk of locoregional recurrence warrants 
the use of adjuvant radiation, there are options for 
shorter courses of radiation that are appropriate for both 
older and younger women. Several randomized trials 
have demonstrated excellent local control and equiva-
lent late effects and quality of life with hypofraction-
ated radiation. The Whelan trial (OCOG) random-
ized 1234 women with node negative, margin negative 
breast cancer to two fractionation schemes 200 cGy for 
25 fractions (the classic NSABP fractionation) versus 
266 cGy for 16 fractions. With long term follow-up, 
there is no difference in local control, survival or late 
toxicity. This trend has received widespread interest, 
and is endorsed by the American Society for Radia-
tion Oncology ‘choose wisely’ initiative [78]. Table 4 
summarizes the relevant randomized trials evaluating 
shorter, hypofractionated radiation schedules.
Adjuvant endocrine therapy
There are two types of endocrine therapies for breast 
cancer – tamoxifen and aromatase inhibitors. Tamox-
ifen is a selective estrogen receptor modulator which 
inhibits estrogen binding to the estrogen receptors in 
breast tissue. In 2005, the Early Breast Cancer Tri-
alists meta-analysis, which analyzed 194 random-
ized trials of adjuvant hormone therapy, showed that 
5 years of adjuvant tamoxifen reduces the annual 
breast cancer death rate by 31% regardless of the use 
of chemotherapy, age, progesterone receptor status 
and other tumor characteristics [8]. As a result, early 
recommendations for adjuvant hormonal therapy 
focused on tamoxifen.
CME
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Newer agents, like the aromatase inhibitors (AIs) 
anastrozole, letrozole and exemestane suppress plasma 
estrogen levels by inhibiting aromatase, the enzyme that 
converts peripheral androgens to estrogens [86]. Several 
large randomized clinical trials have evaluated the ben-
efit of tamoxifen versus AIs, and although there appears 
to be a small improvement in relapse-free survival, there 
is no convincing improvement in overall survival [87].
Endocrine therapies have some important side 
effects. Tamoxifen is generally well tolerated by both 
younger and older patients, with the most frequent 
complaint being hot flashes. There is however a small 
(about 1%) risk of endometrial cancer and venous 
thrombosis associated with 5 years of use of tamoxifen, 
and the recommended annual pelvic examination and 
Papanicolaou (Pap) smear can be a barrier to use for 
some patients. The approximately 1% excess mortality 
from endometrial cancer and venous thromboembo-
lism with tamoxifen is overshadowed in most patients 
by the significant improvement in breast cancer 
survival [49].
Although Als do not increase the risk of endome-
trial cancer or venous thrombosis, they frequently 
cause arthralgias/myalgias that can impede function 
and reduce treatment compliance. AIs are also associ-
ated with accelerated bone loss and an increased risk 
of fracture, which is of particular concern given that 
many older women have osteopenia or osteoporosis 
prior to their breast cancer diagnosis. Older women 
treated with AIs should be recommended to take daily 
vitamin D and calcium supplementation and encour-
aged to engage in routine exercise. For patients with 
osteoporosis or severe osteopenia, treatment with 
bone protective agents, such as bisphosphonates or 
denosumab, should be considered although insurance 
reimbursement may be an obstacle to obtaining such 
therapy. Therapeutic decisions should consider the 
side effect profiles and individual patient characteris-
tics. For example, AIs should be used with caution in 
women with a history of ischemic heart disease and 
osteoporosis, while patients taking tamoxifen need to 
be carefully monitored for the development of venous 
thromboembolism and endometrial carcinoma [88].
Current ASCO guidelines recommend that post-
menopausal women receive either 5 years of an AI, 
5 years of tamoxifen followed by an AI or 10 years 
of tamoxifen [89]. Emerging data have shown benefit 
with this approach and support continuing endocrine 
therapy beyond 5 years. The landmark ATLAS trial 
showed a reduction in recurrence risk and mortal-
ity with 10 versus 5 years of tamoxifen [90] while the 
MA.17 trial comparing letrozole to placebo following 
5 years of adjuvant tamoxifen showed a 43% reduction 
in recurrence in the letrozole arm [91,92]. Ongoing stud-
ies are evaluating the benefit of continuing adjuvant AI 
therapy beyond 5 years.
CME
Table 3. Summary of relevant randomized trials and meta-analyses evaluating omission of radiation in older women 
with breast cancer.
Study (year) Patient population Treatment Results Ref.
Fyles et al. (2004) 769 patients ≥50, path T1 or 
T2, negative margins, path 
negative nodes except for 
≥65 who were also eligible if 
clinically node negative
Whole breast in 
hypofractionated regimen 40 
Gy (16 fx) followed by boost of 
12.5 Gy (5 fx) to lumpectomy 
site. All received tamoxifen
5 year local relapse 0.6% RT 
+ tam 7.7% tam alone. No 
difference in distant relapse or 
overall survival
[75]
Hughes et al. (2004) 
and (2010) CALGB
636 patients ≥70, T1 HR+, 
clinically and/or path node 
negative
Whole breast radiation 45 
Gy in 25 fractions followed 
by boost of 14 Gy (7 fx). All 
received tam
At median follow-up of 
10.5 years, the locoregional 
recurrence was 2% in the RT + 
tam group, 9% in the tam alone 
group. No survival difference
[73,74]
Darby et al. (2011) 
EBCTG
Meta-analysis of individual 
patient data for 10,801 
pts with early stage breast 
cancer who received adjuvant 
radiation (or not) in RCT
Details of RT varied with the 
trials
For a threshold of 10% or 
greater reduction in the 10 year 
recurrence risk, data support 
adjuvant RT for T1 grade 3 
tumors and T2 grade 2 and 3 
tumors for pts ≥70
 [76]
Kunkler et al. (2015) 
Prime II
1326 patients ≥65, LN 
negative, T1-T2 up to 3 cm, 
neg margins; (grade 3 or LVSI 
permitted, but not both)
Whole breast radiation 
(40–50 Gy in 15–25 fx). All 
received endocrine therapy
At median 5 year follow-up, 
ipsilateral breast recurrence 
4.1% in no RT arm vs 1.3% in the 
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Conclusion
Identifying the optimal adjuvant treatment strategy for 
older women with breast cancer is a significant clinical 
challenge given the marked variability in life expec-
tancy and general health in this patient population. In 
our review, we suggest an approach based on life expec-
tancy and geriatric assessment (Figure 2). The sequence 
of administering adjuvant therapies in older women 
with high risk or unfavorable subtype breast cancer 
generally follows a similar pattern to that in younger 
women; chemotherapy first if indicated, followed by 
radiation and finally endocrine therapy and thus these 
treatments will be discussed in that order.
After reviewing the goals of chemotherapy and elic-
iting the patient’s treatment preferences, a brief GA 
can be performed to identify important deficits which 
may affect treatment tolerance, guide multidisciplinary 
intervention and aid treatment selection. GA can also 
help gauge a patient’s functional status, burden of 
comorbidity, general health and overall fitness for ther-
apy. Next, we suggest estimating life expectancy using 
the web-based, combined Lee–Schonberg index risk 
calculator [42]. In general, older women who are in good 
health with an average life expectancy greater than 10 
years and no GA-identified deficits are considered fit 
and should be offered adjuvant chemotherapy perhaps 
with a second generation regimen such as docetaxel/
cyclophosphamide. For these women, various prognos-
tic indices (e.g., Adjuvant! Online and Predict) or molec-
ular based assays (e.g., Oncotype DX) are available to 
help estimate the potential benefits of chemotherapy, 
while tools such as those developed by Hurria et al. 
and the CRASH score are available to aid in estimating 
the risk of chemotherapy toxicities. A discussion of the 
value of chemotherapy mitigated by the risk of toxicity 
and framed within the context of the patient’s values 
and preferences is warranted. If the patient wishes to 
pursue chemotherapy, a third-generation anthracycline-
based and taxane-based regimen either in a standard or 
dose dense fashion depending on the patient’s goals and 
preferences is a reasonable option. However, given the 
modest additional survival benefit with these regimens 
and the risk of cardiac toxicities and secondary hemato-
logic malignancy, a second generation regimen may be 
a more appropriate choice particularly in older women 
with pre-existing heart disease. The second-generation 
docetaxel/cyclophosphamide (TC) regimen was stud-
ied in older women (>65 years old) and was shown to 
be noninferior to the doxorubicin/cyclophosphamide 
regimen and therefore is an attractive option in older 
women when cardiac toxicity is a concern [93].
For older women with HER-2 positive tumors, the 
addition of adjuvant HER-2 directed therapy is recom-
mended if baseline cardiac function is normal and there 
is periodic cardiac monitoring throughout therapy. The 
paclitaxel/trastuzumab (TH) regimen was evaluated in 
the adjuvant setting in patients with early (predomi-
nantly stage I) HER-2 overexpressing breast cancer 
and showed an approximately 2% risk of early recur-
rence [57] suggesting that TH is a reasonable option for 
older women with this breast cancer subtype. Higher 
risk HER-2 positive tumors should be treated with 
more established regimens. Prophylactic granulocyte 
stimulating growth factor is recommended with regi-
mens where there is >20% estimated risk of febrile neu-
tropenia and should be routinely prescribed for women 
over the age of 65 receiving such regimens [94].
For frail older women with limited life expectancy 
(<5 years) and multiple unmodifiable GA-identified 
deficits, such as a high burden of comorbidity or cog-
Table 4. Summary of the relevant randomized trials evaluating hypofractionation of radiation therapy.
Study (year) Patient population Treatment Results Ref.
Yarnold et al. (2005) 
Owen et al. (2006) 
RMH/GOC
1410 patients (T stage 1–3 
with a max of one + node)
Gy/fx#/fx dose/#patients 50/25/2.0 
(470) 42.9/13/3.3 (466) 39/13/3.0 (474)
Median fu 9.7 years, 12% 
local recurrence 10% 15%
[79,80]
Whelan et al. (2002), 
(2010) OCOG
1234 patients LN negative 
margin negative breast ca
Gy/fx#/fx dose/#patients 50/25/2.0 
(612) 42.5/16/2.66 (622)
10 year local recurrence 
6.7% 6.2% No difference 
in cosmesis, survival
[81,82]
Bentzen et al. (2008) 
Haviland et al. (2013) 
START A
2236 patients with breast 
cancer (pT1–3a pN0–1)
Gy/fx#/fx dose/#patients 50/25/2.0 
(749) 41.6/13/3.2 (750) 39/13/3.0 (737)
Median fu 9.3 years, 7% 
local recurrence 6% 9%. 
No difference in late 
toxicity or survival
[83,84]
Bentzen et al. (2008) 
Haviland et al. (2013) 
START B
2215 patients with breast 
cancer (pT1–3a pN0–1)
Gy/fx#/fx dose/#patients 50/25/2.0 
(1105) 40/15/2.67 (1110)
Median fu 9.9 years, 6% 
local recurrence 4%. No 






Figure 2. Suggested general approach to the management of adjuvant chemotherapy in older women with early 
stage breast cancer. 
†Endocrine therapy is only appropriate for patient with hormone receptor positive tumors. 
GA: Geriatric assessment.
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nitive impairment, the benefits of chemotherapy are 
likely be modest and therefore chemotherapy is not 
recommended. For prefrail patients with high risk 
or unfavorable subtype breast cancer and average life 
expectancy of 5–10 years, we suggest multidisciplinary 
interventions prior to chemotherapy treatment for 
those with modifiable GA-identified deficits, or an 
adapted adjuvant treatment approach for those with 
unmodifiable GA identified deficits.
Adjuvant irradiation can be safely omitted in some 
older women without sacrificing a survival advantage if 
they are appropriately treated with adjuvant endocrine 
therapy. These women must be willing to accept a 
slightly higher risk of local recurrence (∼3% at 5 years 
and ∼8% at 10 years) [73,74]. Omitting radiation or pur-
suing shorter radiation schedules (hypofractionation) 
which require fewer treatment visits may be an appeal-
ing option for older women with limited mobility or 
concerns about radiation toxicity.
Because of the preponderance of hormone recep-
tor positive tumors in older women and the fact that 
endocrine therapies are generally well tolerated and 
dramatically reduce the risk of recurrence, adjuvant 
endocrine treatments have become the cornerstone of 
therapy in older women with breast cancer. The major-
ity of older women with this breast cancer subtype are 
generally considered for adjuvant endocrine therapy 
either with tamoxifen or an aromatase inhibitors after 
optimal surgery and radiation therapy (if appropri-
ate). These endocrine agents lower risk of recurrence 
in both the breast and chest wall as well as in distant 
metastatic sites (bone, lung, liver or other organs) by 
about 50% [49].
Applying these principles to the patients in the 
clinical vignette, we note that despite their identical 
chronological age these patients have marked differ-
ent estimated life expectancies (10 year: 92 vs 24%) 
based on the information provided (Table 5). This 
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underscores the importance of GA in identifying 
variables not routinely assessed in clinical evalua-
tion which affect life expectancy, a key consideration 
in adjuvant treatment decisions. Table 5 also shows 
that while Mrs A could likely have derived a reason-
able estimated survival advantage with the addition 
of a 2nd generation chemotherapy regimen (10%) 
with acceptable estimated risk of toxicity (31%), 
Mrs B’s estimated survival benefits are modest 
(5%) and risk of chemotherapy toxicity substantial 
(63%). Furthermore Mrs B has Alzheimer’s disease 
which is likely to limit the overall survival benefits 
of chemotherapy [95] and make treatment compliance 
challenging. Therefore, if it is consistent with her 
goals and preferences, one could recommend chemo-
therapy for Mrs A but likely not offer it to Mrs B. 
Omitting radiation is a reasonable option for both 
women, although considering radiation perhaps with 
a hypofractionated schedule is a reasonable choice 
for Mrs A. Mrs A is also a good candidate for adju-
vant AI therapy; however, worsening arthralgias due 
to underlying osteoarthritis is a concern and should 
be closely monitored. Because AIs are generally well 
tolerated, Mrs B could be considered for a closely 
monitored trial of AI therapy which can be trun-
cated if significant toxicities develop. Tamoxifen is 
an option for either patient but carries the risk of 
venous thromboembolism and endometrial neoplasia 
particularly in the elderly [96].
Future perspective
The landscape of adjuvant breast cancer management 
in older adults is evolving rapidly with several major 
changes in the past two decades and several anticipated 
in the years ahead. The role of geriatric assessment in 
the care of older adults with cancer will likely broaden 
with emerging data showing improved outcomes, 
hence solidifying GA’s role in oncology practice. 
Another anticipated development is the use of biologi-
cal markers of aging such as p16INK4a, in clinical practice 
in addition GA to determine a patient’s molecular age 
and predict tolerance for chemotherapy and other out-
comes. Further, targeted therapies such as everolimus 
and palbociclib have both shown benefits in the meta-
static hormone receptor positive setting and are being 
evaluated in the adjuvant setting. Likewise, chemo-
therapy conjugates of HER-2 directed therapies such as 
ado-trastuzumab are being investigated in the adjuvant 
setting as a way to better target cytotoxic chemother-
apy. Overall the role of cytotoxic chemotherapy in the 
adjuvant setting will probably diminish but will likely 
not disappear completely. Caring for an increasing 
number of older cancer patients will remain a signifi-
cant clinical challenge with the decreasing number of 
geriatrician and increasing, time, resource and person-
nel constraints. To overcome these challenge, health 
policy and workforce changes which bring together 
trained multidisciplinary teams prepared to care for an 
aging breast cancer population will be required.
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Table 5. Life expectancy and adjuvant chemotherapy/endocrine therapy benefit estimates of two 
hypothetical patients
Variable Mrs A Mrs B
Estimated survival irrespective of cancer (%)† 
5 year 98 65
10 year 92 24
10-year mortality risk from cancer (%)‡
Alive 66 33
Die from other causes 11 50
Die from cancer 23 17
Survival benefit (%)‡
AI therapy 6 3
2nd generation chemotherapy + AI 10 5
3rd generation chemotherapy + AI 12 6
Risk of grade 3–5 chemotherapy toxicity (%)§ 
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Executive summary
•	 Older women experience disproportionate breast cancer incidence and mortality.
•	 Increasing life expectancy and an overall aging of the US population will result in an increased number of 
older women with breast cancer in the years ahead.
Treatment goals, patient beliefs & preferences
•	 Many factors influence adjuvant therapy decisions.
•	 Older women with otherwise similar estimates of benefits from adjuvant cancer treatments may arrive at 
different treatment decisions, depending on their goals values and preference.
Evaluation of older women with breast cancer
•	 Geriatric assessment is the cornerstone evaluation of older adults, is prognostic, can identify often undetected 
deficits, guide multidisciplinary intervention and aid in adjuvant treatment decisions.
•	 Several tools are available to estimate life expectancy which is a key consideration in adjuvant treatment 
decisions.
Adjuvant chemotherapy
•	 The goal of adjuvant chemotherapy is to decrease the risk of breast cancer recurrence.
•	 Multivariable indices and molecular-based assays help estimate the benefits of chemotherapy.
•	 Tools incorporating geriatric assessment variables provide estimates of the risk of chemotherapy toxicity.
Adjuvant radiation
•	 Some women with favorable breast cancer features can safely omit radiation without sacrificing a survival 
advantage.
•	 Hypofractionation schedules are a safe and appealing option for older women who require breast radiation.
Adjuvant endocrine therapy
•	 Most women with HR+ breast cancer should be considered for adjuvant endocrine therapy.
Conclusion
•	 The optimal adjuvant management of older women with breast cancer involves weighting the benefits 
of therapy mitigated by the risk of toxicity and framed within the context of the patients’ values and 
preferences.
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To obtain credit, you should first read the journal 
article. After reading the article, you should be able 
to answer the following, related, multiple-choice 
questions. To complete the questions (with a mini-
mum 75% passing score) and earn continuing medi-
cal education (CME) credit, please go to www.med-
scape.org/journal/whe. Credit cannot be obtained for 
tests completed on paper, although you may use the 
worksheet below to keep a record of your answers. 
You must be a registered user on Medscape.org. If 
you are not registered onMedscape.org, please click 
on the “Register” link on the right hand side of the 
website. Only one answer is correct for each question. 
Once you successfully answer all post-test questions 
you will be able to view and/or print your certifi-cate. 
For questions regarding the content of this activity, 
contact the accredited provider, CME@medscape.
net. For technical assistance, contact CME@webmd.
net. American Medical Association’s Physician’s Rec-
ognition Award (AMA PRA) credits are accepted in 
the US as evidence of participation in CME activities. 
For further information on this award, please refer 
to http://www.ama-assn.org/ama/pub/about-ama/
awards/ama-physicians-recognition-award.page. The 
AMA has determined that physicians not licensed in 
the US who participate in this CME activity are eli-
gible for AMA PRA Category 1 Credits™. Through 
agreements that the AMA has made with agencies in 
some countries, AMA PRA credit may be acceptable 
as evidence of participation in CME activities. If you 
are not licensed in the US, please complete the ques-
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Activity evaluation: where 1 is strongly disagree and 5 is strongly agree.
 1 2 3 4 5
The activity supported the learning objectives.
The material was organized clearly for learning to occur.
The content learned from this activity will impact my practice.
The activity was presented objectively and free of commercial bias.
1. Your patient is a 72-year-old woman with breast cancer. According to the review by Dr Jolly and 
colleagues, which one of the following statements about the effect of patient goals, beliefs, 
preferences, and quality-of-life considerations on adjuvant treatment options for older women with 






2. According to the review by Dr Jolly and colleagues, which one of the following statements about 
evaluation of the fitness and suitability of the older patient with breast cancer for adjuvant treatment, 
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3. According to the review by Dr Jolly and colleagues, which one of the following statements about the 
role of adjuvant treatment options, including chemotherapy, endocrine therapy, and radiation therapy 
would most likely be correct? 
£ A The goal of adjuvant chemotherapy is to lessen the existing tumor burden 
£ B Multivariable indices and molecular-based assays help estimate the benefits of chemotherapy, whereas 
geriatric assessment variables provide estimates of the risk for chemotherapy toxicity
£ C Radiation cannot be safely omitted without sacrificing a survival advantage
£ D Adjuvant endocrine therapy is usually unnecessary for most women with hormone receptor-positive breast 
cancer
